Neurofibrillary tangles composed of hyperphosphorylated microtubule-associated protein, tau, and amyloid plaques enriched in ␤-amyloid 42 (A␤ 42 ) 1 are two cardinal pathological hallmarks of Alzheimer's disease (AD) brains (1) . Recently, it was shown that direct injection of A␤ 42 fibrils into the brains of P301L mutant tau transgenic mice (2) or in progenies obtained by crossing JNPL3 mutant tau transgenic mice to Tg2576 mutant amyloid precursor protein transgenic mice (3) accelerated neurofibrillary tangles formation (2, 3) . This finding suggests that amyloid deposits and neurofibrillary tangles development may be related (4) . The A␤-tau relationship is further supported by the fact that primary hippocampal neurons of tau-deficient mice, in contrast to that of the wild type mice, did not show any signs of degeneration upon fibrillar A␤ treatments (5) . Because neurofibrillary tangles are largely composed of paired helical filaments that contained hyperphosphorylated tau protein and treatment of primary neurons with A␤ 42 may result in tau phosphorylation, it is pertinent to understand the molecular signaling entities involved in A␤ 42 -induced tau phosphorylation.
Several studies have demonstrated the interaction between A␤ 42 and the ␣ 7 nicotinic acetylcholine receptors (␣7nAChR) (6 -9) . More importantly, A␤ 42 activates the mitogen-activated kinase cascade protein via the ␣7nAChR (6). This may have major implications for Alzheimer's disease pathology because mitogen-activated kinase cascade protein has been shown to be a tau protein kinase (10, 11) and may be involved in long term potentiation and memory processes (12) (13) (14) . Together with the facts that (a) the A␤ 42 -␣7nAChR interaction modulates neuronal physiological functions that are relevant to memory processes (6, 8, 9) , (b) the ␣7nAChR are distributed in brain regions relevant to memory formation (8, 15) , and (c) the ␣7nAChR are co-localized with amyloid plaques enriched in A␤ 42 and neurons containing abundant intracellular A␤ 42 in Alzheimer's disease brains (8, 16) , there may be a functional relationship linking A␤ 42, ␣7nAChR, and tau.
In this study, we investigated the downstream signaling events of the A␤ 42 -␣7nAChR interaction. We tracked the tau phosphorylation events in response to A␤ 42 stimulation using experimental systems that contain ␣7nAChR including human neuroblastoma cells and brain synaptosomes. Our results suggest that ␣7nAChR is a key mediator of A␤ 42 -induced tau protein phosphorylation.
MATERIALS AND METHODS
Antisense Oligonucleotides-Orthothioate antisense oligonucleotides for human ␣7nAChR (AS1, 5Ј-CCACATAGCTCCCGCCAAGT-3Ј, and AS2, 5Ј-GAAGATGTCCATGTCAGGGTTCAAG-3Ј), human neurokinin receptor 1 (5Ј-CCACTAACACCTCGGAACCCAATCA-3Ј), and a scramble control oligonucleotide (5Ј-ATACACCTGCACACCGTCCG-3Ј) were prepared by BioSource International Inc. (Camarillo, CA). 10 -30 M of each antisense oligonucleotide were added to the SK-N-MC cells and cultured for 4 days with one medium change before analyses. Cellular toxicity was closely monitored by trypan blue exclusion, and consistently Ͼ85% of the cells survived in each of the antisense oligonucleotide treatments.
Peptides and Peptide Preparations-A␤ peptides, galanin, and neuropeptide Y were obtained from Palomar Research Inc (Encinitas, CA). For each experiment, A␤ peptide solutions were freshly prepared in 50 mM HEPES, pH 9.0, to minimize autoaggregation. These A␤ solutions were thoroughly characterized to be devoid of high molecular aggregates (17) . Thus, the A␤ peptides used in this study are mainly present in monomeric, dimeric, and small oligomeric forms.
p-Tau Western Blot Analyses-Hippocampal synaptosomes were prepared according to those described earlier (18) and treated with A␤ 42 or control peptides. At time intervals, an aliquot of the sample was mixed with loading buffer containing 1 mM ␤-mercaptoethanol, 0.1% SDS, 10% glycerol, and 0.01% bromphenol blue and boiled for 5 min before subjecting to denaturing PAGE and the appropriate Western analyses using specific p-tau antibodies (Innogenetics, Temse, Belgium, and BioSource) as described previously (8) .
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In Vitro Tau Kinase Assay-Recombinant tau (1 g, PanVera, Madison, WI) was incubated with 10 units of recombinant activated ERK1 or 0.1 unit of recombinant activated ERK2 (Upstate Biotech. Inc, Lake Placid, NY) in 50 mM HEPES, pH 7.4, containing 10 M ATP, 2 mM Ca 2ϩ , 2 mM Mg 2ϩ , and protease inhibitors (Roche Applied Science) in a final volume of 100 l for various time intervals. At the end of the incubation, aliquots were removed and subjected to denaturing gradient PAGE and Western analyses as described above.
RESULTS
Among the many phosphorylation sites on tau, at least three proline-directed sites (Ser-202, Thr-181, and Thr-231) are phosphorylated in paired helical filaments isolated from AD brains (19) . Specifically, Thr-231 has been shown to directly affect tau binding to microtubules (20) , whereas Ser-202 and Thr-181 modulate the kinetics of tau binding to microtubules (21). Thus, we verified the ability of A␤ 42 to induce the phosphorylation of these three proline-directed sites using three different anti-phosphorylated tau (p-tau) antibodies that recognized p-Ser-202, p-Thr-181, and p-Thr-231, respectively. We treated serum-deprived human neuroblastoma SK-N-MC cells that expressed ␣7nAChR (8) with A␤ 42 and analyzed the tau proteins that were immunoprecipitated from the solubilized cell lysates. Western blot analyses showed that A␤ 42 dose-dependently induced phosphorylation of all of the three sites tested, whereas maximal phosphorylation was obtained with 100 nM A␤ 42 (Fig. 1a) . The kinetics for the Ser-202 phosphorylation appeared to be the fastest and saturated in 15 min while the Thr-181 and Thr-231 phosphorylations were slowly saturated within 1-2 h (Fig. 1b) . The A␤ 42 -induced p-Thr-181 and p-Thr-231 remained for at least 4 h and up to 16 h for p-Ser-202 before returning to ground state, implying the presence of an endogenous dephosphorylation system (Fig. 1b) . Similar A␤ 42 -induced tau phosphorylation was detected using frontal cortical and hippocampal synaptosomes enriched in ␣7nAChR (8, 17) prepared, respectively, from rat or neurologically normal human (data not shown), although the kinetics observed were slightly different. In both rat and human brain synaptosomal preparations, the A␤ 42 -induced p-Ser-202, p-Thr-181, and pThr-231 saturated within 15 min but sustained only for ϳ1 h (rat) or ϳ0.5 h (human), respectively, suggesting the presence of a vigorous and tightly regulated dephosphorylation system for p-tau in vivo. This tau protein phosphorylation event was not induced by A␤ 40-1 or A␤ 42-1 ( Fig. 1c) but effectively suppressed by the ␣7nAChR antagonist, ␣-bungarotoxin (Fig. 1, a  and b) . Furthermore, human Bowes melanoma cells and rat striatum synaptosomes that contain undetectable or low levels of ␣7nAChR (8) failed to generate significant amounts of p-tau upon A␤ 42 treatment under similar experimental conditions (Fig. 1d) .
To further define the involvement of ␣7nAChR in A␤ 42 -induced tau protein phosphorylation, we tested the pharmacological effects of several nAChR ligands. Serum-deprived SK-N-MC cells were treated with the ␣7nAChR antagonist, methyllycaconitine or ␣-bungarotoxin, before the addition of A␤ 42 . Analyses of the immunoprecipitated tau showed that methyllycaconitine and ␣-bungarotoxin attenuated p-tau, whereas the ␣1nAChR antagonist (␣-conotoxin MI), the nonselective nicotinic channel blocker (mecamylamine), and the muscarinic receptor antagonist (atropine) had no effect (Fig.  2a) . In addition, among a panel of A␤ peptide fragments tested, only A␤ [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , the A␤ fragment that may contain a binding epitope for ␣7nAChR (8) , attenuated A␤ 42 -induced tau phosphorylation (Fig. 2b) . On the other hand, only ␣7nAChR agonists such as nicotine (Fig. 2c) and epibatidine but not the ␣4␤2nAChR agonist, cytosine (data not shown), stimulated weak and transient tau phosphorylation. Finally, SK-N-MC cells cultured in the presence of non-toxic concentrations of two different antisense-␣7nAChR oligonucleotides, AS1 and AS2, were used to test the role of the ␣7nAChR in mediating tau phosphorylation. The AS1 and AS2 treatments effectively reduced ␣7nAChR protein levels as verified by Western analysis (Fig. 3a) and significantly diminished A␤ 42 -induced p-tau in serum-deprived SK-N-MC cells (Fig. 3b) . Although AS1 appeared to be more potent than AS2 at high concentrations in suppressing pThr-231, probably indicating some extraneous activities other than reducing ␣7nAChR levels, the cumulative results suggest that ␣7nAChR participate in the A␤ 42 -induced tau phosphorylation process.
Several kinases (22) (23) (24) (25) including glycogen synthase kinase 3␤ (26, 27) and mitogen-activated kinase cascade (7, 8) , in particular the extracellular receptor kinases 1 and 2 (ERKs), have been demonstrated to phosphorylate tau in vitro. To determine the specific kinase(s) involved in the A␤ 42 -␣7nAChR-mediated tau phosphorylation, Western analyses were performed on serum-deprived SK-N-MC cells treated with A␤ 42 using a panel of specific antibodies that recognized the respective active form of glycogen synthase kinase 3␤, P38 kinase, and ERKs. While we consistently failed to detect the A␤ 42 -mediated activation of glycogen synthase kinase 3␤, P38 kinase, Cdk5, or phosphatidylinositol 3-kinase within the time period that correlated tau phosphorylation kinetics in the brain synaptosomes or serum-deprived SK-N-MC cells (data not shown), activation of ERK1 and ERK2 was noted. The respective activation kinetics of ERKs was strikingly similar to that of tau phosphorylation, both ERKs were fully activated within 10 min (Fig 4a) , and the activated ERKs remained detectable up to 4 h (data not shown). This is of particular interest because ERKs have been demonstrated to phosphorylate tau and that neuronal ERKs have been implicated in long term potentiation and memory processes (13, 14) , events that are of primary relevance to AD. In another Western analysis system using
anti-p-tau antibodies, recombinant tau incubated with recombinant activated ERKs in the presence of ATP showed that both ERK1 and ERK2 specifically phosphorylated Ser-202 and Thr-181 but not Thr-231 and that the phosphorylation kinetics was very similar to that observed in the cellular or synaptosome systems (Fig. 4b) . Furthermore, when serum-deprived SK-N-MC cells were separately treated with a panel of specific kinase inhibitors (H-89, chelerythrine, PD169316, PD98059, 5-iodotubercidin, roscovitine, U0126, and SP600125) before exposure to A␤ 42 , only the ERK inhibitors (5-iodotubercidin and roscovitine) and inhibitors of the ERK regulator MEK (PD98059 and U0126) were effective at non-toxic concentrations in suppressing A␤ 42 -induced tau phosphorylation, whereas inhibitors for protein kinase A, protein kinase C, P38, Cdk1, Cdk2, and Cdk5 were ineffective (data not shown). These results further support the involvement of ERKs in the tau protein phosphorylation event.
bars indicate mean Ϯ S.E. c, ␣7nAChR agonist (nicotine) stimulated transient tau phosphorylation. SK-N-MC cells maintained in a 12-well plate were incubated in culture medium containing 0.1% fetal calf serum for 4 h and were treated with nicotine (100 M), and the tissue lysate was subjected to Western analyses as described.
FIG. 2.
Pharmacology of the A␤ 42 -induced tau phosphorylation mediated by ␣7nAChR. SK-N-MC cells maintained in a 12-well plate were incubated in culture medium containing 0.1% fetal calf serum for 4 h and pretreated with 10 M of various cholinergic receptor inhibitors (a) or 10 M of various A␤ peptide fragments (Sigma) and ␣-melanocyte stimulating hormone (MSH) (b) prior to A␤ 42 (100 nM) treatment for 15 min at 37°C. The cells were lysed with 0.1% SDS, and the lysates were assessed for p-tau by Western analyses as described. The mean intensities of each p-tau band (n ϭ 3) were normalized to those of A␤ 42 (taken as 100% inhibition and vehicle control as 0% inhibition) and expressed as relative percent inhibition in the graphs shown on the right. Error   FIG. 3 . SK-N-MC cells were maintained in high glucose Dulbecco's modified Eagle's medium containing 10% fetal calf serum and 10 or 30 M of two separate orthothioate antisense oligonucleotides, AS1 and AS2, against ␣7nAChR for 4 days. Controls include an antisense oligonucleotide NK1 that is directed against the human neurokinin receptor 1 and a scramble oligonucleotide. At the end of the incubation, the cells were serum-deprived by incubating in culture medium containing 0.1% fetal calf serum for 4 h and then either lysed and analyzed simultaneously for ␣7nAChR and ␤-actin (a) or treated with 100 nM of A␤ 42 and then subjected to similar PAGE and Western analyses as described in Fig. 1(b) . Similar data were obtained in two separate experiments.
We have shown that the A␤ 42 -induced tau phosphorylation is mediated by the pentameric cation ion channel ␣7nAChR. Although A␤ 42 behaves as an ␣7nAChR ion channel antagonist that inhibits calcium mobilization and ACh release (17) , it activates kinase(s) including ERKs and behaves as an ␣7nAChR agonist in mediating the tau protein phosphorylation event. Nonetheless, ERKs can only account for the phosphorylation activities on two of the three p-tau sites studied here, because A␤ 42 -induced p-Thr-231 is clearly independent of ERK activities. It is likely that other tau kinases activated by the A␤ 42 -␣7nAChR interaction may account for the Thr-231 phosphorylation that is critically required for maximal inhibition of tau binding to microtubules (21) . Pharmacological studies indicate that a specific c-Jun N-terminal kinase (JNK) inhibitor, SP600125, significantly reduced p-Thr-231, p-Ser-202, and p-Thr-181. Further analyses specifically identified JNK-1 but not JNK-2 to be activated within 10 min by A␤ 42 (Fig. 5a) , and activated JNK-1 remained detectable for up to 4 h (data not shown) in our ␣7nAChR experimental system. The activated JNK-1 efficiently phosphorylates Thr-231 but is relatively less effective in phosphorylating Ser-202 and Thr-181 (Fig. 5b) . Finally, treatment of the SK-N-MC cells with antisense-␣7nAChR oligonucleotides, AS1 and AS2, impaired the ability for A␤ 42 to activate both JNK-1 and ERKs (Fig. 6) . Taken together, these data strongly suggest that JNK-1 and ERKs are the candidate kinases responsible for the A␤ 42 -induced, ␣7nAChR-dependent tau phosphorylation recorded in this study. DISCUSSION We have shown that in experimental systems that contained ␣7nAChR including human neuroblastoma cells and animal and human brain synaptosomes (8, 17, 18) , A␤ 42 effectively induces tau phosphorylation. This A␤ 42 -mediated tau phosphorylation can be appropriately attenuated by ␣7nAChR antagonist or antisense-␣7nAChR, suggesting a critical role of the ␣7nAChR. We further illustrate that ERKs and JNK-1 are concomitantly activated by A␤ 42 in a ␣7nAChR-dependent manner and that these enzymes differentially phosphorylate the three proline-directed serine or threonine residues on tau. Thus, this study attributes ␣7nAChR as a key mediator for A␤ 42 -induced tau phosphorylation. Cruz, CA) using protein A/G-conjugated agarose. After two 10-min washes with phosphate-buffered saline, JNK-1 or JNK-2 in the immunoprecipitates was eluted by boiling in sample preparation buffer for 5 min and then subjected to denaturing 8 -16% PAGE and Western analyses using anti-activated JNK antibodies (Santa Cruz Biotechnology) as described. b, JNK-mediated phosphorylation of tau. Recombinant tau (1 g) was incubated with active JNK-1 or JNK-2 for various time intervals, and aliquots were analyzed by denaturing PAGE and Western analyses using anti-p-tau antibodies. Total tau content in the sample was measured by tau 5 as shown in the top panel. Molecular masses in kDa are presented on the left.
The ␣7nAChR-mediated A␤-induced tau phosphorylation event described here is fully reversible, reflecting a normal cellular response to A␤. Under steady state condition in the brain, the net effect of tau phosphorylation induced by A␤ might be minimal and apparently cannot be responsible for the tau hyperphosphorylation observed in AD brains. Three explanations may account for this discrepancy. First, an inefficient dephosphorylation system (28) that fails to remove p-tau in AD brain may contribute significantly to the p-tau accumulation. Second, chronic presence of A␤ 42 as a result of excess A␤ 42 production and/or deficient A␤ 42 clearance in AD brains may provide a sustained stimulation to generate p-tau. The large amounts of p-tau formed may have exceeded the capacity of the endogenous dephosphorylation system, thereby resulting in net tau hyperphosphorylation. Third, that in addition to soluble A␤ 42 , A␤ fibrils formed as a result of chronic extracellular deposition of A␤ 42 may also contribute to p-tau formation. These A␤ fibrils could directly induce p-tau formation as soluble A␤ by interacting with the same ␣7nAChR or with other unknown surface receptors. Alternately, because A␤ has been demonstrated to accumulate intracellularly in neurons (16, 29, 30) , A␤ fibrils formed inside these neurons may impact on the dephosphorylation pathways, hence indirectly affecting the concentrations of steady state p-tau. Although the interaction of soluble A␤ (monomers, dimers, and oligomers) with ␣7nAChR may reflect early events in AD, the involvement of A␤ fibrils is equally relevant to AD pathogenesis because the concentrations of soluble A␤ in the cerebrospinal fluid actually decline with AD and the presence of A␤ fibrils in AD brains clearly explains this clinical observation. Thus, soluble A␤ and A␤ fibrils together may adequately account for the chronic accumulation of p-tau in AD brains. Nevertheless, these three potential mechanisms, either alone or more likely in concert and perhaps also in conjunction with additional pathological factors such as oxidative stress, may contribute to the abundant and persistent p-tau present in AD brains. The role of oxidative stress is particularly noteworthy because in our cellular experimental system, A␤ 42 failed to induce any detectable tau phosphorylation unless the cells were serum-deprived prior to the A␤ treatment. Since serum deprivation is known to induce stress to cultured cells involving free radicals, these may exacerbate the effects of A␤, leading to the subsequent cascade of signaling events and cellular responses. Alternately, the reduced amount of interfering A␤ 42 -binding proteins in a low serum environment in our experimental system may allow efficient interaction of the exogenous A␤ 42 with the ␣7nAChR resulting in detectable p-tau.
The transient albeit weak effects of ␣7nAChR agonist such as nicotine in stimulating tau phosphorylation further confirm the role of this neuronal ion channel in A␤-induced tau phosphorylation. The differential efficiencies between A␤ 42 and nicotine in stimulating tau phosphorylation could be attributed to their respective binding affinities as well as the molecular recognition epitopes on ␣7nAChR. For example, the affinity of A␤ for ␣7nAChR could be higher than that of nicotine (8, 31) and that the recognition epitope on ␣7nAChR for A␤ 42 is expected to be more complex than that of a smaller molecule, nicotine.
The fact that A␤ [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] could attenuate the A␤ 42 -induced tau phosphorylation is consistent with the initial findings that this peptide fragment inhibited the A␤ 42 -␣7nAChR interaction, both in immunoprecipitation experiment (8) and in electrophysiology studies (9, 32) . Although it implies that the A␤ [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] may contain a necessary contact epitope within A␤ 42 to interact with ␣7nAChR, this interaction is apparently insufficient to activate ␣7nAChR to induce tau phosphorylation. Key contributions from the other sequence components on A␤ 42 in activating ␣7nAChR cannot be excluded. Our results also cannot rule out the possibility, albeit remote, that A␤ 12-28 may negatively regulate the signaling pathway studied in this report via unidentified receptors or mechanisms.
The ␣7nAChR have been shown to interact with the AD pathogenic peptide, A␤ 42 (6 -9, 31) , that may lead to the subsequent internalization of extracellular A␤ 42 into cells (29) . This could be one of the mechanisms contributing to the intracellular accumulation of A␤ 42 observed in AD neurons (16, 30) and even neuronal loss in AD (33) . Here we further demonstrate that the A␤ 42 -␣7nAChR interaction activates mitogenactivated kinase cascade proteins leading to tau protein phosphorylation. Thus, in addition to its physiological roles in memory (34) , its anatomical distribution (15) in brain regions associated with memory functions and the possible participation in the development of dense-core amyloid plaques (16) , the ␣7nAChR may be the molecular mediator linking A␤ 42 to tau phosphorylation. In light of the fact that the A␤ 42 -␣7nAChR interaction modulates several neurochemical processes such as calcium homeostasis, ACh release, and tau phosphorylation that contributed to memory physiology, this may explain why neurons that express ␣7nAChR, such as pyramidal neurons, are vulnerable to A␤ 42 in AD brains. An initial aberrant ␣7nAChR physiology followed by the subsequent "␣7nAChR-expressing" cell loss may be responsible for the memory and cognition impairment observed in earlier stages of AD. A recent hypothesis that synaptic failure caused by diffusible oligomeric A␤ 42 (35) might be a causal factor in AD pathogenesis is especially relevant here because the ␣7nAChRs are located in both the presynaptic and post-synaptic cholinergic and cholinoceptive terminals.
In this series of biochemical, cellular, and pharmacological experiments, we have demonstrated that the ␣7nAChR is a critical linker molecule through which A␤ induces tau phosphorylation by activating ERKs and JNK-1, two candidate tau kinases. Our results are in agreement with the literature that reported similar activation of ERKs and JNK by A␤ 42 , because the cell lines e.g. SH-SY5Y, IMR32, and PC12, and primary cortical and hippocampal neurons employed in those studies all expressed ␣7nAChR as illustrated by Western analyses (8). Clearly, the present study does not preclude the participation of other A␤ receptors that may operate via different signaling mechanisms/pathways, leading to tau phosphorylation. Further explorations using A␤ fibrils and ␣7nAChR-deficient mice will provide more answers to the detailed underlying mechanisms.
